Substance / Medication

Glipizide

Overview

Active Ingredient
glipizide
RxNorm CUI
4821
Labeler: REMEDYREPACK INC.Updated: 2026-02-24T00:00:00.000ZFull label on DailyMed

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

903 trials linked to this intervention

903
Total Trials
103
Recruiting
282
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Clinical pharmacokinetics of glipizide: a systematic review.
Khan Hina, Zamir Ammara, Imran Imran et al. · Expert Opin Drug Metab Toxicol · 2025
PMID: 39267225Meta-Analysis
A rapid and simple UPLC-MS-MS method for determination of glipizide in human plasma and its application to bioequivalence study.
Qiu Xiangjun, Zheng Shuang-li, Wang Yingfei et al. · J Chromatogr Sci · 2015
PMID: 24771054RCT
Effects of pioglitazone and glipizide on platelet function in patients with type 2 diabetes.
Xiao C-C, Ren A, Yang J et al. · Eur Rev Med Pharmacol Sci · 2015
PMID: 25855920RCT
The effects of colesevelam HCl on the single-dose pharmacokinetics of glimepiride, extended-release glipizide, and olmesartan medoxomil.
He Ling, Wickremasingha Prachi, Lee James et al. · J Clin Pharmacol · 2014
PMID: 24019110RCT
Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency.
Arjona Ferreira Juan Camilo, Marre Michel, Barzilai Nir et al. · Diabetes Care · 2013
PMID: 23248197RCTFull text (PMC)
Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide.
Seck Thomas L, Engel Samuel S, Williams-Herman Debora E et al. · Diabetes Res Clin Pract · 2011
PMID: 21477878RCT
Glipizide controlled-release tablets, with or without acarbose, improve glycaemic variability in newly diagnosed Type 2 diabetes.
Bao Yu-Qian, Zhou Jian, Zhou Mi et al. · Clin Exp Pharmacol Physiol · 2010
PMID: 20082624RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Glipizide (substance)
SNOMED CT
387143009
UMLS CUI
C0017642
RxNorm CUI
4821
Labeler
REMEDYREPACK INC.

Clinical Data

This intervention maps to 10 entities in the Healos knowledge graph.

1
Conditions
4
Biomarkers
3
Specialists
0
Symptoms
903
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.